http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-9916579-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afc5d8c9ee6673323cee3e2d19bc5146 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-567 |
| filingDate | 1999-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d974ed0af00d84edb257e63e880ebbe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8336021ebe7df4fe8d2968c3cf46ee19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ede20fe2777b0344fff4d125ebcc94c |
| publicationDate | 2001-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-9916579-A |
| titleOfInvention | Three-phase oral contraceptive |
| abstract | Invention Patent: <B> "THREE-PHASE ORAL CONTRACEPTIVE" <D>. a method of contraception is described in which an estrogen and a progestogen are administered daily in a three-phase sequence for 21 days. In the first phase a combination of an estrogen and a progestin in a low but contraceptively effective daily dosage corresponding to estrogen activity at 23-28 <109> g of 17alpha-ethinylestradiol and progestogen activity at 0.065-0.75 norethindrone is administered by 5-8 days; followed by administration of the same dosage of estrogen and a corresponding progestogen in progestogenic activity at 0.25-1.0 mg of norethindrone for 7-11 days; followed by administration of the same dosage of estrogen and a corresponding progestogen in progestogenic activity at 0.35-2.0 mg of norethindrone for 3-7 days; followed by 4-8 days without administration of either an estrogen or a progestogen. |
| priorityDate | 1998-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.